Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.96 [0.81, 1.13] | | < 1 | | 0% | 1 study (1/-) | 68.5 % | NA | not evaluable | | crucial | - |
progression or deaths (PFS) | 0.87 [0.59, 1.29] | | < 1 | | 0% | 1 study (1/-) | 75.7 % | NA | not evaluable | | important | - |
objective responses (ORR) | 0.91 [0.58, 1.43] | | > 1 | | 0% | 1 study (1/-) | 34.2 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 0.59 [0.31, 1.13] | | < 1 | | 0% | 1 study (1/-) | 94.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 0.81 [0.60, 1.10] | | < 1 | | 0% | 1 study (1/-) | 91.2 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 0.82 [0.38, 1.75] | | < 1 | | 0% | 1 study (1/-) | 69.6 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 0.72 [0.47, 1.12] | | < 1 | | 0% | 1 study (1/-) | 92.7 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (grade 3-4) | 1.10 [0.64, 1.89] | | < 1 | | 0% | 1 study (1/-) | 35.9 % | NA | not evaluable | | non important | - |
SAE (any grade) | 1.22 [0.77, 1.94] | | < 1 | | 0% | 1 study (1/-) | 20.0 % | NA | not evaluable | | non important | - |
STRAE (any grade) | 0.56 [0.35, 0.90] | | < 1 | | 0% | 1 study (1/-) | 99.2 % | NA | not evaluable | | non important | - |
STRAE (grade 3-4) | 0.48 [0.28, 0.84] | | < 1 | | 0% | 1 study (1/-) | 99.5 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.24 [0.17, 0.34] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.34 [0.24, 0.49] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 0.63 [0.11, 3.82] | | < 1 | | 0% | 1 study (1/-) | 69.0 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 0.55 [0.31, 0.99] | | < 1 | | 0% | 1 study (1/-) | 97.8 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (grade 3-4) | 1.28 [0.60, 2.75] | | < 1 | | 0% | 1 study (1/-) | 26.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Adrenal insufficiency TRAE (grade 3-4) | 1.91 [0.06, 57.12] | | < 1 | | 0% | 1 study (1/-) | 35.6 % | NA | not evaluable | | non important | - |
Alopecia TRAE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.01 [0.00, 0.19] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.12 [0.01, 0.94] | | < 1 | | 0% | 1 study (1/-) | 97.8 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 1.91 [0.06, 57.12] | | < 1 | | 0% | 1 study (1/-) | 35.6 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 0.48 [0.02, 14.24] | | < 1 | | 0% | 1 study (1/-) | 66.3 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.24 [0.03, 2.13] | | < 1 | | 0% | 1 study (1/-) | 90.0 % | NA | not evaluable | | non important | - |
Diabetes TRAE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.95 [0.13, 6.81] | | < 1 | | 0% | 1 study (1/-) | 51.9 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.81 [0.27, 2.45] | | < 1 | | 0% | 1 study (1/-) | 64.2 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 1.91 [0.06, 57.12] | | < 1 | | 0% | 1 study (1/-) | 35.6 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 3.83 [0.17, 85.25] | | < 1 | | 0% | 1 study (1/-) | 20.1 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.08 [0.00, 1.41] | | < 1 | | 0% | 1 study (1/-) | 95.6 % | NA | not evaluable | | non important | - |
Nephritis TRAE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.02 [0.00, 0.18] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 3.85 [0.43, 34.59] | | < 1 | | 0% | 1 study (1/-) | 11.6 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 2.88 [0.30, 27.79] | | < 1 | | 0% | 1 study (1/-) | 18.2 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.03 [0.00, 0.42] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.07 [0.00, 1.18] | | < 1 | | 0% | 1 study (1/-) | 96.6 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Alopecia AE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.16 [0.07, 0.34] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 0.95 [0.41, 2.23] | | < 1 | | 0% | 1 study (1/-) | 54.5 % | NA | not evaluable | | non important | - |
Back pain AE (grade 3-4) | 0.32 [0.03, 3.05] | | < 1 | | 0% | 1 study (1/-) | 83.9 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 0.95 [0.06, 15.31] | | < 1 | | 0% | 1 study (1/-) | 51.3 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 1.91 [0.06, 57.12] | | < 1 | | 0% | 1 study (1/-) | 35.6 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 1.44 [0.40, 5.14] | | < 1 | | 0% | 1 study (1/-) | 28.8 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 0.38 [0.07, 1.96] | | < 1 | | 0% | 1 study (1/-) | 87.6 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 1.61 [0.58, 4.47] | | < 1 | | 0% | 1 study (1/-) | 18.2 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 1.20 [0.47, 3.07] | | < 1 | | 0% | 1 study (1/-) | 35.4 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.16 [0.02, 1.31] | | < 1 | | 0% | 1 study (1/-) | 95.6 % | NA | not evaluable | | non important | - |
Neutropenia AE (grade 3-4) | 0.07 [0.02, 0.24] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 0.95 [0.02, 48.21] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 5.76 [0.29, 115.45] | | < 1 | | 0% | 1 study (1/-) | 12.9 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 2.88 [0.30, 27.79] | | < 1 | | 0% | 1 study (1/-) | 18.2 % | NA | not evaluable | | non important | - |
Thrombocytopenia AE (grade 3-4) | 0.05 [0.01, 0.38] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.54 [0.16, 1.86] | | < 1 | | 0% | 1 study (1/-) | 83.5 % | NA | not evaluable | | non important | - |
Weight decreased AE (grade 3-4) | 2.88 [0.30, 27.79] | | < 1 | | 0% | 1 study (1/-) | 18.2 % | NA | not evaluable | | non important | - |